Korea's Reality Contrasts with China's Biotech Sprint
A Lack of Patient Capital Hampers Late-Stage R&D

[Inside Chodong] K-Biotech Has No Patient Capital View original image

"We thought they were chasing us. Then it seemed they were standing beside us, and before we knew it, they had overtaken us."


That was the response of a Korean biotech industry official when asked about the state of China's biotech industry. The biotech installment of our special report, "C-Shock: K-Industries on the Brink," published over four days starting on the 19th, laid bare this reality. Particularly striking is the momentum of a single company developing multiple drug candidates simultaneously and securing several technology licensing deals in just two to three years.


Of course, we do not have to follow China's breakneck pace at all costs, nor is that even possible. What matters is whether we are doing as much as we can. From this perspective, one especially troubling contrast with China is our limited capacity to sustain late-stage development. The further a candidate progresses through clinical trials and the more thoroughly its value is demonstrated, the better the terms a company can secure in a licensing deal. This, in turn, can provide the momentum to develop the next candidate, creating a virtuous cycle.


The reality, however, is that Korean companies, pressed by funding constraints, are scrambling to license out their technologies at relatively low prices during the preclinical stage. About 75% of Korean drug candidates are concentrated in the discovery and preclinical stages, while only around 50 have entered Phase 3 clinical trials. This is one indication of the broader impasse.


At its core is a mismatch between when investors need to recoup their money and when the value of a drug candidate is fully validated. Drug development takes many years, sometimes more than a decade, while investment funds such as venture capital (VC) funds inevitably face pressure from approaching maturity dates. Nor is there an active mergers and acquisitions (M&A) market to provide a backstop. Few companies are willing to step forward, given the burden of shouldering enormous development costs after an acquisition, the difficulty of assessing the likelihood of success, and the industry's unique characteristics and regulatory hurdles.


As a result, industry officials and experts broadly agree that the avenues for recouping investments have not diversified, leaving companies excessively reliant on initial public offerings (IPOs). Companies that urgently need patient capital, such as biotech ventures, face limits in surviving on the technology-based special listing market. Some are pushed into sideline businesses unrelated to their core operations to meet performance requirements, such as revenue, for maintaining their listings. Such cases are a symptom of the darker side of this reality. The key, therefore, is to ensure that follow-on investment for drug development continues even when existing investors recoup their funds. To do so, we need to consider ways to more actively connect investment exits with new investment.


One option would be to link existing investors' sales of their shares with new investments and co-development agreements by large pharmaceutical companies, while expanding the scope of investment based on the results of subsequent development. A company could initially acquire a partial stake to limit its exposure while retaining the option to acquire additional shares or technology rights. A case worth noting is Johnson & Johnson's July co-development agreement with biotech company Sail Biomedicines, which combined an equity investment with an option to acquire the company in the future. Similar deals are increasingly being used in Europe and Japan.



The existence of such options does not mean companies can suddenly step up their investments. The market is still relatively small, and companies have limited capital. This is why the government must provide nuanced support that takes into account the unique characteristics of the biotech industry, including tax incentives for strategic equity investments and co-development, as well as risk-sharing through policy finance. We live in an era when the biotech industry is considered a strategic national security asset. Yet Korea's biotech industry has a precarious structure, with underfunded venture companies holding 78% of all drug candidates. It will be difficult to respond to this reality if the timeline for drug development is dictated by the timeline for recouping investments.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing